{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit 95% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"38.60","upperLimit":"NA","value":"52.70"},{"comment":"Median and 95% CIs was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Duration of response (DOR) based on TVS is defined from the date of the first recorded evidence of response to the first date of documented disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Part 1: Participants received treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks Part 2: Participants also received pexidartinib at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of pexidartinib for oral administration","id":"OG000","title":"Pexidartinib Part 1 and Part 2"},{"description":"Participants that received placebo in part 1 and received Pexidartinib in Part 2 at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of pexidartinib for oral administration","id":"OG001","title":"Placebo Part 1, Pexidartinib Part 2"}],"paramType":"MEDIAN","populationDescription":"DOR was assessed in the ITT population, specifically among the Pexidartinib Part 1, Pexidartinib Part 2; Pexidartinib Part 2 only. Participants randomized to Placebo Part 1 only were not analyzed. DOR was based on numbers of responders only.","reportingStatus":"POSTED","timeFrame":"Date of first documentation of objective response up to date of first documentation of progressive disease, assessed up to end of study (approximately 71 months)","title":"Duration of Response (DOR) Based on Tumor Volume Score (TVS)","type":"SECONDARY","unitOfMeasure":"months"}